Subhash Chand

Dr. Subhash Chand

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Asian Journal of Transfusion Science
Verified
Journal Article
Open access
PDF file
KCKabita Chatterjee
Kabita Chatterjee
SZShamsuz Zaman
Shamsuz Zaman
RCRahul Chaurasia
Rahul Chaurasia
SSSurinder Singh
Surinder Singh
SKShawn D Keil
Shawn D Keil
KSKallol Saha
Kallol Saha
Background and Objectives: This study was conducted to assess the efficacy of Mirasol pathogen reduction system for platelets aimed at preventing bacterial regrowth by spiking buffy coat pooled platelets (BCPP) with clinically relevant load of Staphylococous epidermidis. Materials and Methods: BCPP units were prepared using Teruflex BP-kit with Imugard III-S-PL (Terumo BCT, Tokyo, Japan). Two BCPP units were pooled, of which 40 ml of negative control (NC) was removed. The remaining volume of the platelet unit was inoculated with clinically relevant load of bacteria (total of 30 CFU of S. epidermidis in 1 ml); following this the platelet unit was split into two parts. One part served as positive control (PC) and the other part was subjected to pathogen reduction technique (Mirasol PRT, CaridianBCT Biotechnologies, Lakewood, CO, USA). Bacterial detection was performed using BacT/ALERT system, controls after day 1 and day 7 following inoculation of bacteria and on day 7 for Mirasol-treated unit. Results: Of the 32 treatment cycles, 28 were valid and 4 were invalid. No regrowth was observed in 96.4% (27 of 28) after treatment with Mirasol pathogen reduction system. Of four invalid tests, on two instances the NC showed growth, whereas in other 2 no regrowth was detected in 7th day PC. Bacterial screening of PCs by BacT/ALERT after 24 h of incubation was 28.6%, whereas the effectiveness increased to 100% when incubated for 7 days. Conclusions: Mirasol system was effective in inactivating S.epidermidis when it was deliberately inoculated into BCPP at clinically relevant concentrations. Such systems may significantly improve blood safety by inactivating traditional and emerging transfusion-transmitted pathogens.

10 January 2016 in International Journal of Current Microbiology and Applied Sciences
Verified
Journal Article
Closed access
SCSubhash Chand
Subhash Chand
KSKallol Saha
Kallol Saha
PSPrakash Kumar Singh
Prakash Kumar Singh
SSSmriti Sri
Smriti Sri
NMNeeraj Malik
Neeraj Malik
International Journal of Current Microbiology and Applied Sciences ISSN:2319-7692(Print), ISSN:2319-7706(Online) is a multidisciplinary peer-reviewed journal with reputable academics and experts as members of its Editorial Board. The Current Microbiology aims to publish all the latest and outstanding research articles. Review and letters in all areas of major importance to techniques of microbiology and applied research with publishes high quality of review and research articles on novel aspects of Microbiology including Environmental, Food, Agricultural, Medical, Pharmaceutical, Veterinary, Soil, Water and Biodeterioration.

1 May 2020 in Biologicals
Verified
Journal Article
Closed access
SCSubhash Chand
Subhash Chand
UVUtpreksha Vaish
Utpreksha Vaish
ASAnu Sharma
Anu Sharma
NMNripendra Nath Mishra
Nripendra Nath Mishra
JPJai Prakash Prasad
Jai Prakash Prasad
RMRichi V. Mahajan
Richi V. Mahajan

9 November 2020 in 3 Biotech
Verified
Journal Article
Closed access
PDF file
APAnu Prakash
Anu Prakash
NMNripendra N. Mishra
Nripendra N. Mishra
UVUtpreksha Vaish
Utpreksha Vaish
SSSonia Sharma
Sonia Sharma
AAApoorva Anand
Apoorva Anand
SCSubhash Chand
Subhash Chand

26 December 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
PBPooja Bharali
Pooja Bharali
SCSubhash Chand
Subhash Chand
HCHarish Chander
Harish Chander
Background/Objectives: Trastuzumab is an effective therapeutic intervention for treating HER2-positive breast cancers. The cost-effectiveness, global demand, and patent expiration of trastuzumab have led to the inflow of its biosimilars in the global market. With the rise of biosimilars in the biopharmaceutical market, it has become crucial to ensure that the biosimilar is at par with the original monoclonal antibody (mAb)in terms of efficacy, safety, and quality. Bioassay is one of the critical quality attributes (CQAs), hence developing a reliable and robust bioassay is essential for the evaluation of their biological activity and the harmonization of the quality of these biologics, supporting their safe and effective use in clinical practice. Methods: The present study aimed to develop a robust cell-based bioassay to assess the bioactivity of trastuzumab and its biosimilars for quality control testing. For this purpose, molecular characterization of different HER2-positive breast cancer cell lines of SKBR3, BT474, MDA-MD-453, MDA-MB-175, MCF-7, and MDA-MB-231 was performed to select a suitable cell line for the cell-based bioassay. Results: The SKBR3 cell line was found to express the HER2 receptors significantly higher in comparison to the other cell lines, and it was thereby selected for further bioassay optimization. The biological activity of trastuzumab was determined using the inhibition of proliferation (IOP) assay on the SKBR3, which was optimized based on the parameters of cell seeding density, drug dilution range, and incubation time, and it was further validated as per the compendial guidelines and found valid for the parameters of specificity, accuracy (% relative bias = 0.0067%), precision (repeatability: % GCV = 1.21%), linearity (R2 = 0.99), and range (50% to 200%). Additionally, the biological activity of different trastuzumab biosimilars was assessed using the validated IOP assay and compared to the HER2 binding assay performed by flow cytometry. The biological activity of different trastuzumab biosimilars was found to be comparable to the WHO primary reference standard of trastuzumab in terms of its relative potency using the IOP assay and binding assay by flow cytometry. Conclusions: Thus, an economic and robust cell-based bioassay method was successfully developed to assess the bioactivity of trastuzumab and its biosimilars.

25 June 2018 in Current Science
Verified
Journal Article
Closed access
SCSubhash Chand
Subhash Chand
BKBirendra Kumar
Birendra Kumar
VPVivek Morris Prathap
Vivek Morris Prathap
SSSurinder Singh
Surinder Singh
RMRichi V. Mahajan
Richi V. Mahajan